This phase I trial is evaluating two drugs (one oral and one intravenous) in Acute Myeloid Leukaemia (AML) patients who have gotten worse or not responded to treatment.
This trial is treating patients with Acute Myeloid Leukaemia (AML) .
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
This trial has a single group assignment. Oral Venetoclax and intravenous Dinaciclib will be administered in combination, with different combinations of dose levels explored.
Recruiting Hospitals Read More